|
|
|
46. Transferrin-targeted liposomes entrapping plumbagin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Laskar, P., Mullin, M., Dufès C., Journal of Interdisciplinary Nanomedicine (in press)
45. Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Mullin, M., Dufès C., Journal of Liposome Research (in press)
44. Redox-sensitive, cholesterol-bearing PEGylated poly(propylenimine)-based dendrimersomes for drug and gene delivery to the cancer cells. Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering D., Warzecha, M., Leung, H.Y., Dufès, C. (2018) Nanoscale , 10 (2018) 22830-22847.
43. Challenges and Opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Maniam, G., Mai, C. W., Zulfekeli, M., Dufès, C., Tan, D.M.Y., Fu, J.Y. (2018) Frontiers in Pharmacology, 9 (2018) 1358.
42. Targeted non-viral gene therapy in prostate cancer. Altwaijry, N., Somani, S., Dufes, C. (2018) International Journal of Nanomedicine, 13, 5753-5767.
41. Proof of concept studies for siRNA delivery by cationic non-ionic surfactant vesicles (CN): In vitro and in vivo protein knockdown. Obeid, M. A., Tate, R. J., Mullen, A. B., Dufès, C., Somani, S., Ferro, V. A. (2018) Journal of Liposome Research, 8, 1-27.
40. PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells. Somani, S., Laskar, P., Altwaijry, N., Kewcharoenwong, P., Irving, C., Robb, G., Pickard, B.S.,Dufès, C (2018) Scientific Reports, 8, 9410.
39. Regression of prostate tumours after intravenous administratin of lactoferrin bearing polypropylenimine dendriplexes encoding TNF-alpha, TRAIL and interleukin-12. Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha M., Mackenzie, G.R., Leung, H.Y., Dufès, C. (2018) Drug delivery, 25(1) p. 679-289.
38. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol Karim, R., Somani, S., Al Robaian, M., Mullin, M., Amor, R., McConnell G.,Dufès, C. 28 Jan 2017 In: Journal of Controlled Release. 246, p. 79-87
37. Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex Somani, S., Robb, G., Pickard, B. S. & Dufes, C. 8 Nov 2015 In : Journal of Controlled Release. 217, p. 235-242 8 p
36. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes Lim, L. Y., Koh, P. Y., Somani, S., Al Robaian, M., Karim, R., Yean, Y. L., Mitchell, J., Tate, R. J., Edrada-Ebel, R., Blatchford, D. R., Mullin, M. & Dufès, C. Aug 2015 In : Nanomedicine: Nanotechnology, Biology and Medicine. 11, p. 1445-1454 10 p.
35. Transferrin-bearing dendrimers for cancer therapy: an update Somani, S. & Dufes, C. Jul 2015 In : Nanomedicine. 10, 14, p. 2125-21273p.
34. Anti-cancer efficacy of intravenously administered tumor-targeted vesicles entrapping tocotrienol Fu, J. Y. & Dufès, C. 15 May 2015 In : Pharmaceutical Nanotechnology. 2, 4, p. 172-181 10 p.
33. Applications of dendrimers for brain delivery and cancer therapy Somani, S. & Dufès, C. Oct 2014 In : Nanomedicine. 9, 15, p. 2403-2414 12 p.
32. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain Somani, S., Blatchford, D. R., Millington, O., Stevenson, M. L. & Dufès, C. 28 Aug 2014 In : Journal of Controlled Release. 188, p. 78-86 9 p.
31. E2F1 drives chemotherapeutic drug resistance via ABCG2 Rosenfeldt, M., Bell, L., Long, J., O'Prey, J., Nixon, C., Roberts, F., Dufès, C. & Ryan, K. 2014 In : Oncogene. 33, p. 4164-4172 9 p.
30. Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight dependent transport processes El-Hammadi, M. M., MacLellan, S., Dufès, C., Holmes, W. M., Condon, B., Uchegbu, I. F. & Schatzlein, A. G. 2014 In : Pharmaceutical Nanotechnology. 2, 3, p. 129-137 9 p.
29. The application of nanotechnology in medicine: treatment and diagnostics Owain, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J., Katti, K., Sokolov, K., Mazza, M., Fontaine, O., Rannard, S. & Stone, V. 2014 In : Nanomedicine. 9, 9, p. 1291-1294 4 p.
28. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas Al Robaian, M. M. M., Chiam, K. Y., Blatchford, D. & Dufès, C. 2014 In : Nanomedicine. 9, 4, p. 421-434 4 p
27. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Dufès, C., Al Robaian, M. M. M. & Somani, S. May 2013 In : Therapeutic Delivery. 4, 5, p. 629-640 12 p.
26. Dendrimer-Based Drug Delivery Systems: From Theory to Practice Edited by Yiyun Cheng Dufès, C. Feb 2013 In : ChemMedChem. 8, 2, p. 336 1 p.
25. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration Lemarié, F., Chang, C. W., Blatchford, D., Amor, R., Norris, G., Tetley, L., McConnell, G. & Dufès, C. 2013 In : Nanomedicine. 8, 2, p. 181-192 12 p.
24. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system Lemarié, F., Croft, D., Tate, R., Ryan, K. M. & Dufès, C. 2012 In : Biomaterials. 33, p. 2701-2709 9 p.
23. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy Wilkinson, S., Croft, D., O’Prey, J., Meedendorp, A., O’Prey, M., Dufès, C. & Ryan, K. M. Nov 2011 In : Autophagy. 7, 11, p. 1295-1301 7 p.
22. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex Aldawsari, H. M., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L. & Dufès, C. Sep 2011 In : Biomaterials. 32, 25, p. 5889-5899 11 p.
21. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration Fu, J. Y., Zhang, W., Blatchford, D., Tetley, L., Mcconnell, G. & Dufès, C. 25 Aug 2011 In : Journal of Controlled Release. 154, 1, p. 20-26 7 p.
20. Drug and gene delivery systems Dufès, C. & Watson, D. G. (ed.) Jan 2011 Pharmaceutical Chemistry. First ed. p. 581-590 632 p.
19. Brain delivery of peptides and proteins Dufès, C. 2011 Peptide and protein delivery. van der Walle, C. (ed.). 1st ed. Vol. 1, p. 105-122 18 p.
18. Delivery of the vitamin E compound tocotrienol to cancer cells Dufès, C. 2011 In : Therapeutic Delivery. 2, 11, p. 1385-1389 5 p.
17. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polyethylenimine polyplex Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L. & Dufès, C. 2011 In : Nanomedicine: Nanotechnology, Biology and Medicine. 7, 5, p. 815-823 9 p.
16. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA Koppu, S., Oh, Y. J., Edrada-Ebel, R., Blatchford, D. R., Tetley, L., Tate, R. & Dufès, C. 19 Apr 2010 In : Journal of Controlled Release. 143, 2, p. 215-221 7 p.
15. Enhanced transfection efficacy of polyethylenimine by surface modification with arginine, lysine, and leucine Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R. & Dufès, C. 2010 In : Controlled Release Society Newsletter. 27, 6, p. 12-14 3 p.
14. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles Fu, J. Y., Blatchford, D. R., Tetley, L. & Dufès, C. 3 Dec 2009 In : Journal of Controlled Release. 140, 2, p. 95-99 5 p.
13. Polymers and dendrimers for gene delivery in gene therapy Uchegbu, I. F., Dufès, C. M., Kan, P. L., Schätzlein, A. G. & Templeton, N. S. (ed.) 6 Oct 2008 Gene and cell therapy: therapeutic mechanisms and strategies 3rd ed. p. 321-339 18 p.
12. High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil Holmes, W. M., Maclellan, S., Condon, B., Dufès, C., Evans, T. R. J., Uchegbu, I. F. & Schätzlein, A. G. 2008 In : Physics in Medicine and Biology. 53, p. 505-513 8 p.
11. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo Bell, H. S., Dufès, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., Schätzlein, A. G., Vousden, K. H. & Ryan, K. M. 2 Apr 2007 In : Journal of Clinical Investigation . 117, 4, p. 1008-1018 11 p.
10. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Qu, X., Khutoryanskiy, V. V., Stewart, A., Rahman, S., Papahadjopoulos-Sternberg, B., Dufès, C., McCarthy, D., Wilson, C. G., Lyons, R., Carter, K. C., Schätzlein, A. & Uchegbu, I. F. 2006 In : Biomacromolecules. 7, 12, p. 3452-3459 7 p.
9. Dendrimers in gene delivery Dufès, C., Uchegbu, I. F. & Schätzlein, A. G. 2005 In : Advanced Drug Delivery Reviews. 57, 15, p. 2177-2202 25 p.
8. Preferential liver gene expression with polypropylenimine dendrimers Schätzlein, A. G., Zinselmeyer, B. H., Elouzi, A., Dufès, C., Chim, Y. T. A., Roberts, C. J., Davies, M. C., Munro, A., Gray, A. I. & Uchegbu, I. F. 2005 In : Journal of Controlled Release. 101, 1-3, p. 247-258 12 p.
7. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors Dufès, C., Keith, W. N., Bilsland, A., Proutski, I., Uchegbu, I. F. & Schätzlein, A. G. 2005 In : Cancer Research. 65, 18, p. 8079-84 7995 p.
6. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles Dufès, C., Muller, J-M., Couet, W., Olivier, J-C., Uchegbu, I. F. & Schätzlein, A. G. 2004 In : Pharmaceutical Research. 21, 1, p. 101-7 94 p.
5. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain Dufès, C., Gaillard, F., Uchegbu, I. F., Schätzlein, A. G., Olivier, J-C. & Muller, J-M. 2004 In : International Journal of Pharmaceutics. 285, 1-2, p. 77-85 9 p.
4. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats Dufès, C., Olivier, J-C., Gaillard, F., Gaillard, A., Couet, W. & Muller, J-M. 2003 In : International Journal of Pharmaceutics. 255, 1-2, p. 87-97 11 p.
3. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro Dufès, C., Alleaume, C., Montoni, A., Olivier, J-C. & Muller, J-M. 2003 In : Journal of Molecular Neuroscience. 21, 2, p. 91-102 11 p.
2. Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery McPhail, D., Tetley, L., Dufès, C. & Uchegbu, I. F. 2000 In : International Journal of Pharmaceutics. 200, 1, p. 73-86 14 p.
1. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting Dufès, C., Schätzlein, A. G., Tetley, L., Gray, A. I., Watson, D. G., Olivier, J. C., Couet, W. & Uchegbu, I. F. 2000 In : Pharmaceutical Research.17, 10, p. 1250-1258 9 p.
45. Development of transferrin-bearing vesicles encapsulating aspirin for cancer therapy. Sakpakdeejaroen, I., Somani, S., Mullin, M., Dufès C., Journal of Liposome Research (in press)
44. Redox-sensitive, cholesterol-bearing PEGylated poly(propylenimine)-based dendrimersomes for drug and gene delivery to the cancer cells. Laskar, P., Somani, S., Altwaijry, N., Mullin, M., Bowering D., Warzecha, M., Leung, H.Y., Dufès, C. (2018) Nanoscale , 10 (2018) 22830-22847.
43. Challenges and Opportunities of nanotechnology as delivery platform for tocotrienols in cancer therapy. Maniam, G., Mai, C. W., Zulfekeli, M., Dufès, C., Tan, D.M.Y., Fu, J.Y. (2018) Frontiers in Pharmacology, 9 (2018) 1358.
42. Targeted non-viral gene therapy in prostate cancer. Altwaijry, N., Somani, S., Dufes, C. (2018) International Journal of Nanomedicine, 13, 5753-5767.
41. Proof of concept studies for siRNA delivery by cationic non-ionic surfactant vesicles (CN): In vitro and in vivo protein knockdown. Obeid, M. A., Tate, R. J., Mullen, A. B., Dufès, C., Somani, S., Ferro, V. A. (2018) Journal of Liposome Research, 8, 1-27.
40. PEGylation of polypropylenimine dendrimers: effects on cytotoxicity, DNA condensation, gene delivery and expression in cancer cells. Somani, S., Laskar, P., Altwaijry, N., Kewcharoenwong, P., Irving, C., Robb, G., Pickard, B.S.,Dufès, C (2018) Scientific Reports, 8, 9410.
39. Regression of prostate tumours after intravenous administratin of lactoferrin bearing polypropylenimine dendriplexes encoding TNF-alpha, TRAIL and interleukin-12. Altwaijry, N., Somani, S., Parkinson, J. A., Tate, R. J., Keating, P., Warzecha M., Mackenzie, G.R., Leung, H.Y., Dufès, C. (2018) Drug delivery, 25(1) p. 679-289.
38. Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol Karim, R., Somani, S., Al Robaian, M., Mullin, M., Amor, R., McConnell G.,Dufès, C. 28 Jan 2017 In: Journal of Controlled Release. 246, p. 79-87
37. Enhanced gene expression in the brain following intravenous administration of lactoferrin-bearing polypropylenimine dendriplex Somani, S., Robb, G., Pickard, B. S. & Dufes, C. 8 Nov 2015 In : Journal of Controlled Release. 217, p. 235-242 8 p
36. Tumor regression following intravenous administration of lactoferrin- and lactoferricin-bearing dendriplexes Lim, L. Y., Koh, P. Y., Somani, S., Al Robaian, M., Karim, R., Yean, Y. L., Mitchell, J., Tate, R. J., Edrada-Ebel, R., Blatchford, D. R., Mullin, M. & Dufès, C. Aug 2015 In : Nanomedicine: Nanotechnology, Biology and Medicine. 11, p. 1445-1454 10 p.
35. Transferrin-bearing dendrimers for cancer therapy: an update Somani, S. & Dufes, C. Jul 2015 In : Nanomedicine. 10, 14, p. 2125-21273p.
34. Anti-cancer efficacy of intravenously administered tumor-targeted vesicles entrapping tocotrienol Fu, J. Y. & Dufès, C. 15 May 2015 In : Pharmaceutical Nanotechnology. 2, 4, p. 172-181 10 p.
33. Applications of dendrimers for brain delivery and cancer therapy Somani, S. & Dufès, C. Oct 2014 In : Nanomedicine. 9, 15, p. 2403-2414 12 p.
32. Transferrin-bearing polypropylenimine dendrimer for targeted gene delivery to the brain Somani, S., Blatchford, D. R., Millington, O., Stevenson, M. L. & Dufès, C. 28 Aug 2014 In : Journal of Controlled Release. 188, p. 78-86 9 p.
31. E2F1 drives chemotherapeutic drug resistance via ABCG2 Rosenfeldt, M., Bell, L., Long, J., O'Prey, J., Nixon, C., Roberts, F., Dufès, C. & Ryan, K. 2014 In : Oncogene. 33, p. 4164-4172 9 p.
30. Size-tuneable nanometric MRI contrast agents for the imaging of molecular weight dependent transport processes El-Hammadi, M. M., MacLellan, S., Dufès, C., Holmes, W. M., Condon, B., Uchegbu, I. F. & Schatzlein, A. G. 2014 In : Pharmaceutical Nanotechnology. 2, 3, p. 129-137 9 p.
29. The application of nanotechnology in medicine: treatment and diagnostics Owain, A., Dufès, C., Moscatelli, D., Mayes, E., Lovell, J., Katti, K., Sokolov, K., Mazza, M., Fontaine, O., Rannard, S. & Stone, V. 2014 In : Nanomedicine. 9, 9, p. 1291-1294 4 p.
28. Therapeutic efficacy of intravenously administered transferrin-conjugated dendriplexes on prostate carcinomas Al Robaian, M. M. M., Chiam, K. Y., Blatchford, D. & Dufès, C. 2014 In : Nanomedicine. 9, 4, p. 421-434 4 p
27. Transferrin and the transferrin receptor for the targeted delivery of therapeutic agents to the brain and cancer cells Dufès, C., Al Robaian, M. M. M. & Somani, S. May 2013 In : Therapeutic Delivery. 4, 5, p. 629-640 12 p.
26. Dendrimer-Based Drug Delivery Systems: From Theory to Practice Edited by Yiyun Cheng Dufès, C. Feb 2013 In : ChemMedChem. 8, 2, p. 336 1 p.
25. Antitumor activity of the tea polyphenol epigallocatechin-3-gallate encapsulated in targeted vesicles after intravenous administration Lemarié, F., Chang, C. W., Blatchford, D., Amor, R., Norris, G., Tetley, L., McConnell, G. & Dufès, C. 2013 In : Nanomedicine. 8, 2, p. 181-192 12 p.
24. Tumor regression following intravenous administration of a tumor-targeted p73 gene delivery system Lemarié, F., Croft, D., Tate, R., Ryan, K. M. & Dufès, C. 2012 In : Biomaterials. 33, p. 2701-2709 9 p.
23. The cyclin-dependent kinase PITSLRE/CDK11 is required for successful autophagy Wilkinson, S., Croft, D., O’Prey, J., Meedendorp, A., O’Prey, M., Dufès, C. & Ryan, K. M. Nov 2011 In : Autophagy. 7, 11, p. 1295-1301 7 p.
22. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polypropylenimine polyplex Aldawsari, H. M., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L. & Dufès, C. Sep 2011 In : Biomaterials. 32, 25, p. 5889-5899 11 p.
21. Novel tocotrienol-entrapping vesicles can eradicate solid tumors after intravenous administration Fu, J. Y., Zhang, W., Blatchford, D., Tetley, L., Mcconnell, G. & Dufès, C. 25 Aug 2011 In : Journal of Controlled Release. 154, 1, p. 20-26 7 p.
20. Drug and gene delivery systems Dufès, C. & Watson, D. G. (ed.) Jan 2011 Pharmaceutical Chemistry. First ed. p. 581-590 632 p.
19. Brain delivery of peptides and proteins Dufès, C. 2011 Peptide and protein delivery. van der Walle, C. (ed.). 1st ed. Vol. 1, p. 105-122 18 p.
18. Delivery of the vitamin E compound tocotrienol to cancer cells Dufès, C. 2011 In : Therapeutic Delivery. 2, 11, p. 1385-1389 5 p.
17. Enhanced gene expression in tumors after intravenous administration of arginine-, lysine- and leucine-bearing polyethylenimine polyplex Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R., Tetley, L. & Dufès, C. 2011 In : Nanomedicine: Nanotechnology, Biology and Medicine. 7, 5, p. 815-823 9 p.
16. Tumor regression after systemic administration of a novel tumor-targeted gene delivery system carrying a therapeutic plasmid DNA Koppu, S., Oh, Y. J., Edrada-Ebel, R., Blatchford, D. R., Tetley, L., Tate, R. & Dufès, C. 19 Apr 2010 In : Journal of Controlled Release. 143, 2, p. 215-221 7 p.
15. Enhanced transfection efficacy of polyethylenimine by surface modification with arginine, lysine, and leucine Aldawsari, H. M., Sundara Raj, B., Edrada-Ebel, R., Blatchford, D., Tate, R. & Dufès, C. 2010 In : Controlled Release Society Newsletter. 27, 6, p. 12-14 3 p.
14. Tumor regression after systemic administration of tocotrienol entrapped in tumor-targeted vesicles Fu, J. Y., Blatchford, D. R., Tetley, L. & Dufès, C. 3 Dec 2009 In : Journal of Controlled Release. 140, 2, p. 95-99 5 p.
13. Polymers and dendrimers for gene delivery in gene therapy Uchegbu, I. F., Dufès, C. M., Kan, P. L., Schätzlein, A. G. & Templeton, N. S. (ed.) 6 Oct 2008 Gene and cell therapy: therapeutic mechanisms and strategies 3rd ed. p. 321-339 18 p.
12. High-resolution 3D isotropic MR imaging of mouse flank tumours obtained in vivo with solenoid RF micro-coil Holmes, W. M., Maclellan, S., Condon, B., Dufès, C., Evans, T. R. J., Uchegbu, I. F. & Schätzlein, A. G. 2008 In : Physics in Medicine and Biology. 53, p. 505-513 8 p.
11. A p53-derived apoptotic peptide derepresses p73 to cause tumor regression in vivo Bell, H. S., Dufès, C., O'Prey, J., Crighton, D., Bergamaschi, D., Lu, X., Schätzlein, A. G., Vousden, K. H. & Ryan, K. M. 2 Apr 2007 In : Journal of Clinical Investigation . 117, 4, p. 1008-1018 11 p.
10. Carbohydrate-based micelle clusters which enhance hydrophobic drug bioavailability by up to 1 order of magnitude Qu, X., Khutoryanskiy, V. V., Stewart, A., Rahman, S., Papahadjopoulos-Sternberg, B., Dufès, C., McCarthy, D., Wilson, C. G., Lyons, R., Carter, K. C., Schätzlein, A. & Uchegbu, I. F. 2006 In : Biomacromolecules. 7, 12, p. 3452-3459 7 p.
9. Dendrimers in gene delivery Dufès, C., Uchegbu, I. F. & Schätzlein, A. G. 2005 In : Advanced Drug Delivery Reviews. 57, 15, p. 2177-2202 25 p.
8. Preferential liver gene expression with polypropylenimine dendrimers Schätzlein, A. G., Zinselmeyer, B. H., Elouzi, A., Dufès, C., Chim, Y. T. A., Roberts, C. J., Davies, M. C., Munro, A., Gray, A. I. & Uchegbu, I. F. 2005 In : Journal of Controlled Release. 101, 1-3, p. 247-258 12 p.
7. Synthetic anticancer gene medicine exploits intrinsic antitumor activity of cationic vector to cure established tumors Dufès, C., Keith, W. N., Bilsland, A., Proutski, I., Uchegbu, I. F. & Schätzlein, A. G. 2005 In : Cancer Research. 65, 18, p. 8079-84 7995 p.
6. Anticancer drug delivery with transferrin targeted polymeric chitosan vesicles Dufès, C., Muller, J-M., Couet, W., Olivier, J-C., Uchegbu, I. F. & Schätzlein, A. G. 2004 In : Pharmaceutical Research. 21, 1, p. 101-7 94 p.
5. Glucose-targeted niosomes deliver vasoactive intestinal peptide (VIP) to the brain Dufès, C., Gaillard, F., Uchegbu, I. F., Schätzlein, A. G., Olivier, J-C. & Muller, J-M. 2004 In : International Journal of Pharmaceutics. 285, 1-2, p. 77-85 9 p.
4. Brain delivery of vasoactive intestinal peptide (VIP) following nasal administration to rats Dufès, C., Olivier, J-C., Gaillard, F., Gaillard, A., Couet, W. & Muller, J-M. 2003 In : International Journal of Pharmaceutics. 255, 1-2, p. 87-97 11 p.
3. Effects of the vasoactive intestinal peptide (VIP) and related peptides on glioblastoma cell growth in vitro Dufès, C., Alleaume, C., Montoni, A., Olivier, J-C. & Muller, J-M. 2003 In : Journal of Molecular Neuroscience. 21, 2, p. 91-102 11 p.
2. Liposomes encapsulating polymeric chitosan based vesicles - a vesicle in vesicle system for drug delivery McPhail, D., Tetley, L., Dufès, C. & Uchegbu, I. F. 2000 In : International Journal of Pharmaceutics. 200, 1, p. 73-86 14 p.
1. Niosomes and polymeric chitosan based vesicles bearing transferrin and glucose ligands for drug targeting Dufès, C., Schätzlein, A. G., Tetley, L., Gray, A. I., Watson, D. G., Olivier, J. C., Couet, W. & Uchegbu, I. F. 2000 In : Pharmaceutical Research.17, 10, p. 1250-1258 9 p.
